FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150
Research-grade compound with certificate of analysis. Full analytical testing on every lot.
CJC-1295 (no DAC) + GHRP-2 leverages complementary growth hormone (GH) axis stimulations through distinct receptor mechanisms. These peptides can engage two distinct upstream regulatory pathways that influence endogenous GH release. Combined, they can provide a model for evaluating dual-pathway stimulation of pituitary activity, pulsatile hormone dynamics, and downstream metabolic signalling.
CJC--1295 without DAC (also called Mod GHF1-29) is a synthetic and chemically modified form of growth hormone–releasing hormone (GHRH) without containing the drug affinity complex (DAC) [1]. This dramatically shortens the peptide's half-life, thus more closely mimicking the natural pulsatile endogenous GHRH secretion. It produces a brief rise in growth hormone (GH) and insulin growth factor-1 that clears quickly from circulation rather than prolonged stimulation. In contrast, when CJC-1295 with DAC binds to albumin, it can persist for multiple days, thereby sustaining GHRH receptor stimulation [1].
CJC-1295 without DAC is structurally derived from GRF(1-29), the biologically active component of GHRH [2, 3]. Unlike sermorelin, which has natural amino acids, CJC-1295 without DAC has stabilizing substitutions, including D-amino modifications at position 2. As a result, this version of CJC-1295 resists dipeptidyl peptidase-4 degradation and has prolonged activity while preserving receptor affinity [2, 3]. This is thought to shorten exposure time, reduce the risk of receptor desensitization, and avoid chronically elevated baseline GH. Because it acts and clears quickly, it can be timed around sleep when GH naturally peaks and paired strategically with a GHRP that offers easier dosing adjustments.
Growth Hormone Releasing Peptide-2 (GHRP-2) is a synthetic ghrelin receptor agonist peptide [4]. It mimics the action of the gut-derived hormone ghrelin, which influences hunger [4]. Ghrelin naturally binds to the growth hormone secretagogue receptor GHS-R1a. GHS-R1a is found in both the pituitary gland and the hypothalamus [4]. GHRP-2 was developed as a research compound to stimulate growth hormone secretion through this ghrelin pathway [4].
Both GHRP-2 and CJC-1295 stimulate GH secretion through two distinct, yet complementary, receptor pathways [1, 4].
GHRP-2 activates ghrelin receptor GHS-R1a, engaging calcium-mediated signalling that promotes acute GH release [5]. When GHRP-2 binds to GHS-R1a in the pituitary, GHRP-2 stimulates growth hormone release in a pulsatile manner [6]. Whereas, in the hypothalamus, GHRP-2’s binding to GHS-R1a activates appetite pathways [6]. Unlike CJC-1295 or other GHRH analogs, GHRP-2 activates a different intracellular pathway involving Gq/11 signalling, calcium influx, and amplification of GH secretion [7]. This allows GHRP-2 to work synergistically with GHRH analogs.
In contrast, CJC-1295 acts at the GHRH receptor to enhance cAMP-mediated GH synthesis and secretion [2].
Combined, this dual-pathway stimulation is hypothesized to support both the amplitude and duration of GH secretion, potentially preserving physiologic pulsatility while extending the overall GH exposure window. Both GHS-R1a and GHRH analog converge on pituitary somatotroph activation. GHRP-2 predominantly drives PKC/Ca2+-linked signalling that amplifies secretory output, whereas GHRH receptor signalling is cAMP/PKA-mediated, supporting GH synthesis and release.
In vitro studies show that combined GHRH and CHRP-2 increase GH release and transcriptional signaling more than either alone, suggesting dual-pathway synergistic effects [8].
in vivo and clinical evidence also confirm that the combination of GHRH and GHRP-2 produces stronger growth hormone responses [9, 10]. Human studies using GHRH(1-29) in combination with GHRP-2 show greater GH increases than with single-peptide administration [9]. In hypogonadal men, GHRP-2 administration alone can induce up to 47-fold GH increase, and up to 54-fold increase when combined with GHRH [11]. Animal studies show similar results, with combined stimulation leading to significantly amplified GH release [10].
The combined formula, using similar potencies, is geared toward balancing receptor engagement. Because both peptides act on different but complementary pathways, using equivalent doses may provide proportional activation of both the GHRH receptor and the ghrelin receptor.
References:
1 Ionescu, M. and Frohman, L. A. (2006) Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J. Clin. Endocrinol. Metab., The Endocrine Society 91, 4792–4797
2 Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., et al. (2005) Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, The Endocrine Society 146, 3052–3058
3 Scarborough, R., Gulyas, J., Schally, A. V. and Reeves, J. J. (1988) Analogs of growth hormone-releasing hormone induce release of growth hormone in the bovine. J. Anim. Sci., Oxford University Press (OUP) 66, 1386–1392
4 Laferrère, B., Abraham, C., Russell, C. D. and Bowers, C. Y. (2005) Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J. Clin. Endocrinol. Metab., The Endocrine Society 90, 611–614
5 Ghigo, E., Arvat, E., Muccioli, G. and Camanni, F. (1997) Growth hormone-releasing peptides. Eur. J. Endocrinol., Oxford University Press (OUP) 136, 445–460
6 Bowers, C. Y., Momany, F. A., Reynolds, G. A. and Hong, A. (1984) On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology, The Endocrine Society 114, 1537–1545
7 Gondo, R. G., Aguiar-Oliveira, M. H., Hayashida, C. Y., Toledo, S. P., Abelin, N., Levine, M. A., et al. (2001) Growth hormone-releasing peptide-2 stimulates GH secretion in GH-deficient patients with mutated GH-releasing hormone receptor. J. Clin. Endocrinol. Metab., The Endocrine Society 86, 3279–3283
8 Yan, M., Hernandez, M., Xu, R. and Chen, C. (2004) Effect of GHRH and GHRP-2 treatment in vitro on GH secretion and levels of GH, pituitary transcription factor-1, GHRH-receptor, GH-secretagogue-receptor and somatostatin receptor mRNAs in ovine pituitary cells. Eur. J. Endocrinol., Oxford University Press (OUP) 150, 235–242
9 Bowers, C. Y. and Granda-Ayala, R. (1996) GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans. J. Pediatr. Endocrinol. Metab., J Pediatr Endocrinol Metab 9 Suppl 3, 261–270
10 Argente, J., García-Segura, L. M., Pozo, J. and Chowen, J. A. (1996) Growth hormone-releasing peptides: clinical and basic aspects. Horm. Res., S. Karger AG 46, 155–159
11 Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., et al. (2020) Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl. Androl. Urol., AME Publishing Company 9, S149–S159
Every lot undergoes five independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 4-panel testing protocol: HPLC purity analysis, ESI-MS identity confirmation, LAL endotoxin screening, and amino acid analysis (for peptides >15 residues). Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders placed before noon PST, Monday–Saturday, ship the same day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and amino acid analysis where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 10+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). CJC1295 (No DAC) + GHRP-2 is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.
